Shoshana Levy Lab In the Division of Oncology

Shoshana Levy, PhD: Publications

Search PubMed for article abstracts

1. Yaffe D and Fuchs S: Autoradiographic study of the incorporation of [3H]-uridine during myogenesis in tissue culture. Dev Biol 15:33-50, 1967.

2. Levy S, Simpson RT and Sober HA: Fractionation of chromatin components. Biochemistry 11:1547-1554, 1972.

3. Levy S and Simpson RT: Quantitative immunochemical search for single-stranded DNA in chromatin. Nature New Biol 241:139-141, 1973.

4. Levy R, Levy S, Rosenberg SA and Simpson RT: Selective stimulation of nonhistone chromatin protein synthesis in lymphoid cells by phytohemagglutinin. Biochemistry 12:224-228, 1973.

5. Levy S, Wood P, Grunstein M and Kedes LH: Identification by template activity of the fractionated messenger RNA for individual histones. Cell 4:239, 1975.

6. Levy S and Aviv H: Quantitation of labeled globin messenger RNA by hybridization with excess complementary DNA covalently bound to cellulose. Biochemistry 15:1844, 1976.

7. Aviv H, Voloch Z, Bastos R and Levy S: Biosynthesis and stability of globin mRNA in cultured erythroleukemic Friend cells. Cell 8:495, 1976.

8. Levy S, Childs G and Kedes LH: Sea urchin nuclei use RNA polymerase II to transcribe discrete histone RNAs larger than messengers. Cell 15:151, 1978.

9. Childs G, Levy S and Kedes LH: Rapid purification of biologically active individual histone mRNAs by hybridization to cloned DNA linked to cellulose. Biochemistry 18:208, 1979.

10. Levy S, Sures I and Kedes LH: Nucleotide sequence of the 5' end of Strongylocentrotus purpuratus H2b histone mRNA and its location within the histone DNA sequence. Nature 279:737, 1979.

11. Sures I, Levy S and Kedes LH: Leader sequences of S. purpuratus histone mRNAs start at a unique heptanucleotide common to all five histone genes. Proc Nat Acad Sci 77:1265, 1980.

12. Mauron A, Levy S, Childs G and Kedes LH: Monocistronic transcription is the physiological mechanism of sea urchin embryonic histone gene expression. Mol Cell Biol 1:661, 1981.

13. Levy S, Sures I and Kedes LH: The nucleotide and amino acid coding sequence of a gene for H1 histone that interacts with euchromatin: the early embryonic H1 gene of the sea urchin Strongylocentrotus purpuratus. J Biol Chem 257:9438, 1982.

14. Bergman Y, Stewart S, Levy S and Levy R: Biosynthesis, glycosylation and in vitro translation of the human T cell antigen Leu-4. J Immunol 131:1876, 1983.

15. Fujimoto J, Levy S and Levy R: Spontaneous release of the Leu-2 (T8) molecule from human T cells. J Exp Med 158:752, 1983.

16. Thielemans K, Rothbard JB, Levy S and Levy R: Syngeneic anti-idiotypic immune responses to a B cell lymphoma. J Exp Med 163:19, 1985.

17. Cleary ML, Meeker TC, Levy S, Lee B, Trela M, Sklar J and Levy R: Clustering of extensive somatic mutations in the immunoglobulin heavy chain variable region gene of a human B cell lymphoma. Cell 44:97, 1986.

18. Carroll WL, Lowder JN, Streifer R, Warnke R, Levy S and Levy R: Idiotype variant cell populations in patients with B cell lymphoma. J Exp Med 164:1566, 1986.

19. Levy S, Mendel E and Kon S: A rapid method for cloning and sequencing variable-region genes of expressed immunoglobulins. Gene 54:167, 1987.

20. Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S and Levy R: Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 139:2825, 1987.

21. Kon S, Levy S and Levy R: Retention of an idiotypic determinant in a human B-cell lymphoma undergoing immunoglobulin variable-region mutation. Proc Nat Acad Sci USA 84:5053, 1987.

22. Levy R, Levy S, Cleary JL, Carroll W, Kon S, Bird J and Sklar J: Somatic mutation in human B cell tumors. Imm Reviews 96:43-58, 1987.

23. Levy S, Mendel E, Kon S, Avnur Z and Levy R: Mutational hot-spots in immunoglobulin V region genes of human follicular lymphomas. J Exp Med 168:475, 1988.

24. Carroll WL, Mendel E and Levy S: Hybridoma fusion cell lines contain an aberrant kappa transcript. Mol Immunol 25:991, 1988.

25. Carroll WL, Starnes CO, Levy R and Levy S: Alternative Vk gene rearrangements in a murine B cell lymphoma. An explanation for idiotypic heterogeneity. J Exp Med 168:1607, 1988.

26. Berinstein N, Levy S and Levy R: Activation of an excluded immunoglobulin allele in a human B lymphoma cell line. Science 244:337, 1989.

27. Benjamini E, Andria ML, Levy S, Leung CY: Studies on the clonality of the antibody response to a protein epitope. Adv Exp Med Biol 251:99, 1989.

28. Levy S, Campbell MJ and Levy R: Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline Vk genes to downstream Jk segments in a murine B cell line. J Exp Med 170:1, 1989.

29. Berinstein N, Campbell MJ, Lam K, Carswell C, Levy S and Levy R: Idiotypic variation in a human B cell line. J Immunol 144:752, 1990.

30. Andria ML, Levy S and Benjamini E: Different amino acid sequences constitute the combining sites of antibodies to the same protein epitope. J Immunol 144:2614, 1990.

31. Oren R, Takahashi S, Doss C, Levy R and Levy S: TAPA-1, the target of an anti-proliferative antibody defines a new family of transmembrane proteins. Mol Cell Bio 10:4007, 1990.

32. Takahashi S, Levy S, and Levy R: TAPA-1, the target of an anti-proliferative antibody, is associated on the cell surface with the Leu-13 antigen. J Immunol, 145: 2207, 1990.

33. Levy S, Nguyen VQ, Andria ML, Takahashi S: Structure and membrane topology of TAPA-1: J Biol Chem 2666:14597, 1991.

34. Andria ML, Hsieh C-L, Oren R, Francke U, and Levy S: Genomic organization and chromosomal localization of the TAPA-1 gene. J Immunol 147:1030, 1991.

35. Bahler DW, Campbell MJ, Hart S, Miller R, Levy S and Levy R: Immunoblobulin VH expression among human follicular lymphomas. Blood 78:1561, 1991.

36. Campbell MJ, Zelenetz AD, Levy S, Levy R: Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol 29:193, 1992.

37. Andria ML, Barsh GS, and Levy S: Expression of TAPA-1 in preimplantation mouse embryos. Biochem Biophys Res Com 188:1201,1992.

38. Bradbury LE, Kansas GS, Levy S, Evans RL and Tedder TF: The CD19/CD21 signal transducing complex of human B lymphocytes includes the TAPA-1 and Leu-13 molecules. J Immunol 149:2841,1992.

39. Schick MR, Nguyen VQ and Levy S: Anti-TAPA 1 antibodies induce protein tyrosine phosphorylation that is prevented by increasing intracellular thiol levels. J Immunol 151: 1918, 1993.

40. Schick MR, and Levy S: The TAPA-1 molecule is associated on the surface of B-cells with HLA-DR molecules. J Immunol 151: 4090, 1993.

41. Rajagopalan K, Pavlinkova G, Levy S, Pokkuluri PR, Schiffer M, Haley B and Kohler H. Novel unconventional binding site in the variable region of immunoglobulins. Proc Nat Acad Sci 93:6019-6024, 1996.

42. Secrist H, Levy S, DeKruyff R, Umetsu DT. Ligation of TAPA-1 (CD81) or major histocompatibility complex class II in co-cultures of human B and T lymphocytes enhances interleukin-4 synthesis by antigen-specific CD4+ T cells. European J of Immunology 26:1435-1442, 1996.

43. Hakim I, Levy S and Levy R. A nine amino acid peptide from IL-1b augments anti tumor immune responses induced by protein and DNA vaccines. J Immunol 157:5503-5511, 1996.

44. Kim TS, DeKruyff RH, Rupper R, Maecker H, Levy S, and Umetsu DT. An Ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 158:4137-4144, 1997.

45. Maecker HT and Levy S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med 185:1505-1510, 1997.

46. Maecker, HT, Todd SC, and Levy S. The tetraspanin superfamily: molecular facilitators. FASEB Journal 11:425-442, 1997.

47. Maecker H, Umetsu DT, DeKruyff R and Levy S. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. Vaccine 15: 1687-1696, 1997.

48. Caspar, CB, Levy S, and Levy R. Idiotype vaccines for non-Hodgkin lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 90:3699-3706, 1997.

49. Maecker HT, Do, MS and Levy S. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc Natl. Acad. Sci. USA 95:2458-2462, 1998.

50. Todd SC, Doctor VS and Levy S. Sequences and expression of six new members of the tetraspanin/TM4SF family, Biochem. Biophys. Acta 1399:101-104, 1998.

51. Levy S, Todd SC, and Maecker HT. CD81 (TAPA-1), a molecule involved in signal transduction and cell adhesion in the immune system. Ann Rev Immunol 16: 89-109, 1998.

52. Maecker HT, Umetsu DT, DeKruyff RH, Levy S. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. J. Immunol 161:6532-6536, 1998.

53. McCormick AA, Kumagai MH, Hanley K, Turpen TH, Hakim I, Grill LK, Tuse D, Levy S, Levy R. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitope in tobacco plants. Proc Natl. Acad. Sci. USA 96:703-708, 1999.

54. Flint M, Thomas JM, Maidens CM, Shotton C, Levy S, Barclay S, McKeating JA. Functional analysis of cell surface expressed Hepatitis C virus E2 glycoprotein. J. Virol. 73:6782-6790, 1999.

55. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA. Characterization of Hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol.73:6235-6244, 1999.

56. Maecker HT, Todd SC, Kim EC, Levy S. Differential expression of murine CD81 highlighted by new anti-mouse CD81 monoclonal antibodies. Hybridoma. 19:15-22, 2000.

57. Higginbottom A, Quinn ER , Kuo CC, Flint M, Wilson LH, Bianchi E, Nicosia A, Monk PN, McKeating JA and Levy S. Identification of Amino Acid Residues in CD81 Critical for Interaction with Hepatitis C Virus Envelope Glycoprotein E2. J. Virol. 74: 3642-3649, 2000.

58. Hadlock KG, Lanford R, Perkins S, Rowe J, Qing Y, Levy S, Abriganani S, Foung SKH. Human monoclonal antibodes to highly conserved domains on hepatitis C virus E2 protein. J. Virol. 74: 10407-10416, 2000.

59. Meola A, Sbardellati A, Bruniercole B, Cerretani M, Pezzanera M, Ceccacci A, Vitelli A, Levy S, Nicosia A, Traboni C, McKeating JA Scarselli E. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J. Virol. 74: 5933-5938, 2000.

60. Deng J., Yeung PV, Tsitoura D, Dekruyff RH, Dale T. Umetsu DT, and Levy S. Allergen-Induced Airway Hyperreactivity is diminished in CD81 Deficient Mice. J. Immunol 165: 5054-5061, 2000.

61. Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, Umetsu DT. Vaccination with Allergen-IL-18 Fusion DNA Protects Against, and Reverses Established, Airway Hyperreactivity in a Murine Asthma Model: Dependence on IFNg and CD8+ T Cells. J. Immunol. 166: 959-965, 2001.

62. Chan CH, Hadlock KG, Foung SKH and Levy S. Preferential Expression of the Immunoglobulin VH 1-69 (51p1) Gene in an anti-Hepatitis C Virus Immune Response. Blood 97: 1023-1026, 2001.

63. Auffermann-Gretzinger S, Keeffe EB and Levy S. Impaired Dendritic Cell Maturation in Individuals with Chronic but not Resolved Hepatitis C Virus Infection. Blood 97: 3171-3176, 2001.

64. Kelic S, Levy S, and David E. Weinstein DE. CD81 Regulates Neuron-Induced Astrocyte Cell-Cycle Exit. Mol. Cell Neurosci. 17: 551-560, 2001.

65. VanCompernolle SE, Levy S and Todd SC. Anti-CD81 activates LFA-1 on T cells and promotes T cell- B cell collaboration. Eur. J. Immunol 31:823-831, 2001.

66. Walter DM, Wong CP, DeKruyff RH, Berry GJ, Levy S, Umetsu DT. IL-18 Gene Transfer by Adenovirus Prevents the Development of and Reverses Established Allergen-Induced Airway Hyperreactivity. J. Immunol. 166: 6392-6398, 2001.

67. Flint M, Quinn ER and Levy S. In Search of Hepatitis C Virus (HCV) Receptors (s). Clinics in Liver Disease 5: 873-93, 2001.

68. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 98:3745-3749, 2001.

69. Zhao X, Tang ZY, Klumpp B, Wolff-Vorbeck G, Barth H, Levy S, von Weizsacker F, Blum HE, Baumert TF. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J Clin Invest 109:221-32, 2002.

70. Deng J., Dekruyff R H, Freeman GJ, Umetsu DT, and Levy S. Critical Role of CD81 in Cognate T Cell - B Cell Interactions Leading to Th2 Responses. Inter. Immunl. 14: 513-523, 2002

71. .Geisert EE, Williams RW, Geisert GR, Fan L, Asbury AM, Maecker HT, Deng J and Levy S. Increased Brain size and glial cell number in CD81-null Mice. J. Comp. Neurol., 453:22-32, 2002.

72. Masciopinto, F., Freer G., Burgio, V. L., Levy, S., Galli-Stampino, L., Bendinelli, M., Houghton, M., Abrignani, S., Uematsu, Y. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 304: 187-196, 2002.

73. Silvie O, Rubinstein E, Franetich JF, Prenant M, Belnoue E, Renia L, Hannoun L, Eling W, Levy S, Boucheix C, Mazier D. Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat Med 9:93-96 2003.

74. Cocquerel L, Quinn ER, Flint M, Hadlock KG, Foung SKH, Levy S. Recognition of Native Hepatitis C Virus E1E2 Heterodimers by a Human Monoclonal Antibody. J. Virol. 77: 1604-1609, 2003.

75. Weng WK and Levy S. Hepatitis C virus and Lymphomagenesis. Leukemia and Lymphoma, 44: 1113-1120, 2003.

76. Cocquerel L, Kuo CC, Dubuisson J, Levy S. CD81-Dependent binding of Hepatitis C virus E1E2 heterodimers. J Virol 77: 10677-10683, 2003.

77. Shoham T, Rajapaksa R, Boucheix C, Rubinstein E, Poe JC, Tedder TF, Levy S. The tetraspanin CD81 regulates the expression of CD19 during B cell development in a post endoplasmic reticulum compartment. J Immunol. 171: 4062-4072, 2003.

78. Feigelson SW, Grabovsky V, Shamri R, Levy S, Alon R. The CD81 tetraspanin facilitates instantaneous leukocyte VLA-4 adhesion strengthening to VCAM-1 under shear flow. J. Biol Chem 278: Oct 7 51203-51212, 2003.

79. Cherukuri A, Shoham T, Sohn HW, Levy S, Brooks S, Carter R, Pierce SK. The tetraspanin CD81 is necessary for partitioning of coligated CD19/CD21-B cell antigen receptor complexes into signaling-active lipid rafts. J Immunol. 172:370-380, 2004.

top

Stanford Medicine Resources:

Footer Links: